BIOGRAPHIES
OF IBA EXECUTIVE MANAGERS
Yves Jongen
Chief Research Officer and Managing Director, based in Louvain-la-Neuve, Belgium
Yves Jongen is Chief Research Officer for Ion Beam Applications. After founding IBA in 1986, he
served as general manager and co-general manager of the company until March 2000, when he
assumed his current role. Founded in Louvain-la-Neuve, Belgium, IBA has become a world leader in
particle accelerator technology and its applications, particularly in medical imaging, cancer therapy
and sterilization.
Prior to founding IBA, Mr. Jongen served for 16 years as manager of the UCL Cyclotron Research
Center, a multidisciplinary organization established by the Catholic University of Louvain-la-Neuve
(UCL), with several cyclotrons for fundamental and applied research. He holds a dozen patents and is
the author of approximately 200 publications in the particle accelerator field and their applications.
Mr. Jongen graduated cum laude from UCL in 1970 as a civil engineer in electronics and earned an
additional certificate in nuclear sciences. He has received the Georges Vanderlinden prize for science,
awarded by the Belgium Royal Academy, for his work in physics and electricity, and shared the
magazine Trends-Tendances “1997 Entrepreneur of the Year” honors for the French-speaking part of
Belgium with the former CEO of IBA, Pierre Mottet.
Olivier Legrain
Chief Executive Officer, based in Louvain-la-Neuve, Belgium
Olivier Legrain, 43 years old, married and father of two children, graduated in economics from the
Free University of Brussels (ULB) in 1992. After four years as auditor with Didier Claes and
Associates, he joined IBA in 1996 as Controller and was particularly involved in the IPO of the
company. In 1998, he was appointed Chief Financial Officer (CFO) of Scanditronix Medical AB
Sweden, the new subsidiary of IBA Dosimetry activities. He then returned to the Belgian headquarters
for a period of two years before taking the roles of Chairman and Chief Executive Officer (CEO) of
Wellhöfer Scanditronix AB from 2001 to 2003. After having successfully led the dosimetry branch of
operations, Olivier Legrain took control of IBA Molecular in 2003 as President. In 2011, he became
responsible for establishing the future strategy of the IBA Group with the role of Chief Strategy Officer
(CSO) and became, in May 2012, the new CEO of the IBA Group.
October 2012
www.iba-protontherapy.com
1